Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
urbanists.social is one of the many independent Mastodon servers you can use to participate in the fediverse.
We're a server for people who like bikes, transit, and walkable cities. Let's get to know each other!

Administered by:

Server stats:

570
active users

urbanists.social: AboutProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.7

#rsv

34 posts14 participants2 posts today
Continued thread
Public
Angus Andrea Grieve-Smith

I wish I could say that #flu and #RSV cases were going down faster in #NYC, but I'm glad to see that they're still going down. No sign of an out-of-season wave or a shallow trough!

Let's hope that COVID rates will also go down, and we'll have a nice quiet, safe spring and summer for infectious disease transmission!

Influenza positive test results in NYC Highlights for week ending April 5, 2025 (Week 14) 3,566 specimens were positive for influenza, a 20% decrease from the previous week; 20% were positive for influenza 337 specimens were positive for RSV, a 18% decrease from the previous week. Influenza-like illness visits were at 5% of all weekly visits. There were no influenza-associated pediatric deaths reported this week. Season to date, a total of ten influenza- There were three influenza outbreaks reported from long-term care facilities this week. Season to date, a total of 139 Source PDF (source) (cache) Source New York City Department of Health and Mental Hygiene (data) RSV positive test results in NYC Source PDF (source) (cache) Source New York City Department of Health and Mental Hygiene (data)
Outpatient influenza-like illness visits in NYC by season As of April 5, 2025, the rate was about 5%, lower than it was a year ago, but still higher than in 2021, 2022 and 2023.
Replied in thread
Public
Jeanine B. aus H.

mir diese Ignoranz nicht geben kann!

Wenn mein Vati aufgrund eines Infektes stirbt, weil so ein ignoranter Mensch 'Vulnerable nicht schützen' wollte, kann man dann eigentlich Krankenhauskosten, etc. als Schadensersatz einklagen? Frage für ne Freundin

Was ich die Schnauze voll hab, glaubt man mir erst, wenn ich M's werfe

#Corona#SARSCoV2#Influenza
Continued thread
Public
RiffReporter

Zuletzt gab es auch Rückschläge in der Gesundheitsforschung: Moderna hat seine mRNA-#Studie für einen #RSV-Impfstoff für Säuglinge gestoppt. Wie gefährlich ist das #Virus für Babys und welche Schutzmöglichkeiten gibt es zurzeit? #archiv #impfung riffreporter.de/de/wissen/rsv-

Ein neugeborenes Baby mit geschlossenen Augen und einer blauen Mütze umfasst den Zeigefinger eines Erwachsenen.
RiffReporter · mRNA-Impfstoff gegen das RS-Virus: Studienstopp bei SäuglingenBy Ulrike Gebhardt
Continued thread
Public
Angus Andrea Grieve-Smith

COVID numbers are going up, but #flu and #RSV cases continue to drop in #NYC. We still don't have accurate hospitalization numbers for #influenza and #RSVirus here, but it looks like the overall risk of hospitalization and death from acute airborne infectious diseases is dropping.

I'm going to plan for indoor dining and singing, and maybe travel, but as long as this many people are dying and being hospitalized I'll #WearAMask in elevators, trains, doctor's offices, pharmacies and supermarkets!

Influenza positive test results in NYC Highlights for week ending March 29, 2025 (Week 13) 4,465 specimens were positive for influenza, a 18% decrease from the previous week; 23% were positive for influenza 409 specimens were positive for RSV, a 12% decrease from the previous week. Influenza-like illness visits were at 6% of all weekly visits. There was one influenza-associated pediatric death reported this week. Season to date, a total of ten influenza- There were three influenza outbreaks reported from long-term care facilities this week. Season to date, a total of 136 Source PDF (source) (cache) Source New York City Department of Health and Mental Hygiene (data) RSV positive test results in NYC Source PDF (source) (cache) Source New York City Department of Health and Mental Hygiene (data)
Outpatient influenza-like illness visits in NYC by season The curve drops fairly fast in February, but then much slower in March, finally dropping below the previous year's count in the week ending March 29,
Public
Howard Smith MD, AM

A novel, bivalent RSV vaccine provides lasting protection against respiratory syncytial viral disease over two rather than only one season. #RSV #bivalent #vaccine #renoir #pfizer #universityrochester
instagram.com/drhowardsmithrep

InstagramHoward G. Smith MD, AM on Instagram: "A Longer-Lasting RSV Vaccine A novel, bivalent RSV vaccine provides lasting protection against respiratory syncytial viral disease over two rather than only one season. This the result of a phase 3 so-called RENOIR trial that tested 36,862 participants 60 to over 80 years of age at 241 sites in 7 countries. Helmed by University of Rochester infectious disease researchers, it was just reported in the Clinical Infectious Diseases journal. The vaccine, developed by Pfizer, contains both RSV-A and RSV-B antigens. Tested against a placebo, the vaccine provided 88.9% protection from one month after immunization through the first season and 77.8% protection through the second season. The already available monovalent RSV vaccines from both Pfizer and GSK are verified protective for only one season. This bivalent vaccine, named RSVPreF, can be safely and effectively co-administered with both the influenza vaccines and the CoVid vaccines. That provides a comprehensive shield against that trio of potentially deadly viral respiratory diseases in only one visit to your medical team or neighborhood pharmacy. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf061/8006665?login=false https://www.medscape.com/viewarticle/bivalent-rsv-vaccine-shows-sustained-efficacy-and-safety-2025a10006y0 #RSV #bivalent #vaccine #renoir #pfizer #universityrochester"0 likes, 0 comments - drhowardsmithreports on April 2, 2025: "A Longer-Lasting RSV Vaccine A novel, bivalent RSV vaccine provides lasting protection against respiratory syncytial viral disease over two rather than only one season. This the result of a phase 3 so-called RENOIR trial that tested 36,862 participants 60 to over 80 years of age at 241 sites in 7 countries. Helmed by University of Rochester infectious disease researchers, it was just reported in the Clinical Infectious Diseases journal. The vaccine, developed by Pfizer, contains both RSV-A and RSV-B antigens. Tested against a placebo, the vaccine provided 88.9% protection from one month after immunization through the first season and 77.8% protection through the second season. The already available monovalent RSV vaccines from both Pfizer and GSK are verified protective for only one season. This bivalent vaccine, named RSVPreF, can be safely and effectively co-administered with both the influenza vaccines and the CoVid vaccines. That provides a comprehensive shield against that trio of potentially deadly viral respiratory diseases in only one visit to your medical team or neighborhood pharmacy. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf061/8006665?login=false https://www.medscape.com/viewarticle/bivalent-rsv-vaccine-shows-sustained-efficacy-and-safety-2025a10006y0 #RSV #bivalent #vaccine #renoir #pfizer #universityrochester".
ExploreLive feeds
About